Drug intelligence / Profile preview

mRNA shingles vaccine

Development stage: Unknown
Lead developer: AIM Vaccine Co.
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The mRNA shingles vaccine is a prophylactic vaccine candidate developed by Ningbo Rong'an Biological Pharmaceutical, a subsidiary of AIM Vaccine Co., Ltd., for the prevention of shingles (herpes zoster). Utilizing a messenger RNA (mRNA) platform, the vaccine is designed to instruct host cells to express a specific antigen from the Varicella-Zoster Virus (VZV), typically Glycoprotein E, to elicit a robust protective immune response. This approach aims to provide a more efficient and potentially safer alternative to traditional live-attenuated or protein subunit vaccines. The candidate is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and immunogenicity.

Other names: messenger ribonucleic acid shingles vaccinemRNA-HZ

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on mRNA shingles vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA shingles vaccine.

Explore the full profile